MDxHealth SA (NASDAQ:MDXH) Receives $7.75 Consensus PT from Brokerages

Shares of MDxHealth SA (NASDAQ:MDXH) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.75.

Several research analysts have weighed in on MDXH shares. TD Cowen upped their price objective on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. BTIG Research reissued a “buy” rating and set a $7.00 target price on shares of MDxHealth in a research report on Tuesday, December 23rd. Lake Street Capital raised their price target on shares of MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Kennedy Capital Management LLC purchased a new position in MDxHealth during the 3rd quarter worth $1,826,000. FreeGulliver LLC lifted its position in shares of MDxHealth by 25.7% during the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after purchasing an additional 65,000 shares in the last quarter. Mink Brook Asset Management LLC boosted its holdings in MDxHealth by 64.9% during the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after purchasing an additional 103,686 shares during the last quarter. Renaissance Technologies LLC grew its position in MDxHealth by 23.3% in the 4th quarter. Renaissance Technologies LLC now owns 250,100 shares of the company’s stock worth $893,000 after purchasing an additional 47,300 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in MDxHealth by 96.0% in the 4th quarter. Russell Investments Group Ltd. now owns 194,097 shares of the company’s stock worth $693,000 after purchasing an additional 95,054 shares in the last quarter.

MDxHealth Stock Performance

Shares of MDxHealth stock opened at $3.61 on Friday. The stock has a market capitalization of $178.70 million, a PE ratio of -5.64 and a beta of 1.64. MDxHealth has a 52 week low of $1.35 and a 52 week high of $5.33. The stock has a 50 day moving average price of $3.52 and a two-hundred day moving average price of $3.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.